Published in Oncol Lett on June 06, 2017
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
The nuclear receptor superfamily: the second decade. Cell (1995) 24.99
Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature (1986) 11.35
Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A (1996) 10.94
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
Combinatorial control of gene expression by nuclear receptors and coregulators. Cell (2002) 8.01
Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev (1999) 7.06
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res (2009) 5.20
ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett (1996) 4.77
Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A (1985) 4.58
The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology (1999) 3.67
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57
Role of estrogen receptor beta in estrogen action. Annu Rev Physiol (2001) 2.40
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat (2013) 2.26
Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol (2000) 2.07
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene (2000) 1.62
Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer? Cancer Res (1999) 1.55
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
ERbeta in breast cancer--onlooker, passive player, or active protector? Steroids (2008) 1.42
Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. Cancer Res (2007) 1.33
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene (2001) 1.29
Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer (2006) 1.29
Global analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulation. BMC Genomics (2011) 1.28
Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol (2004) 1.23
Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. J Cell Biochem Suppl (2001) 1.14
Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol (2009) 1.13
ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene (2004) 1.12
Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett (2006) 1.03
Nuclear and cytoplasmic expressions of ERβ1 and ERβ2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat (2010) 1.02
HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol (2000) 1.00
Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res (2011) 0.97
Aromatase and the breast: regulation and clinical aspects. Maturitas (2006) 0.96
Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol (2014) 0.95
Chromogenic in situ hybridization in tumor pathology. Methods Mol Med (2004) 0.93
The intracrinology of breast cancer. J Steroid Biochem Mol Biol (2014) 0.92
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Breast Cancer Res Treat (2014) 0.86
Estrogen receptor-beta and breast cancer: translating biology into clinical practice. Steroids (2012) 0.84
Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands. Breast Cancer Res Treat (2009) 0.83
Support of a bi-faceted role of estrogen receptor β (ERβ) in ERα-positive breast cancer cells. Endocr Relat Cancer (2014) 0.83
Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer. FEBS J (2013) 0.82
Co-expression of ER-beta and HER2 associated with poorer prognosis in primary breast cancer. Clin Invest Med (2009) 0.81
Synergistic Activation of ERα by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1. Cancer Res (2016) 0.79
Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Eur J Cancer (2014) 0.78
Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia. Turk Patoloji Derg (2012) 0.76